Volume 12, Number 6, June 2006

Mixed Cryptosporidium Infections and HIV

Vitaliano Cama,*† Robert H. Gilman,†‡ Aldo Vivar,§ Eduardo Ticona,¶ Ynes Ortega,# Caryn Bern,* and Lihua Xiao*
*Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Johns Hopkins University, Baltimore, Maryland, USA; ‡Asociación Benéfica Proyectos en Informática, Salud, Medicina y Agricultura, Lima, Peru; §Hospital Arzobispo Loayza, Lima, Peru; ¶Hospital Dos de Mayo, Lima, Peru; and #University of Georgia, Griffin, Georgia, USA

Figure. Multilocus polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP) analysis of specimens previously identified as Cryptosporidium canis and C. felis. A) Agarose gel electrophoresis of PCR-amplified products of specimens previously identified as C. canis (lanes 1–3) and C. felis (lanes 4 and 5) with molecular tools based on the small subunit (SSU) rRNA, dihydrofolate reductase (DHFR), and Cryptosporidium oocyst wall protein (COWP). Molecular markers in all photos are 100-bp ladders. B) RFLP analysis of DHFR-based PCR amplification products using BpuA I restriction enzyme; lanes 1, 4, and 5 are C. hominis; lane 2 is C. parvum; and lane 3 is C. meleagridis. C) RFLP analysis of COWP-based PCR amplification products using Rsa I restriction enzyme; lanes 1, 4, and 5 are C. hominis; lane 2 is C. parvum; and lane 3 is C. meleagridis. D) RFLP analysis of the SSU-based PCR products using restriction enzymes Ssp I (left) and Vsp I (right); the combined patterns for lanes 1 to 3 correspond to C. canis and lanes 4 and 5 to C. felis.

EID Home | Top of Page | Ahead-of-Print | Past Issues | Suggested Citation | EID Search | Contact Us | Accessibility | Privacy Policy Notice | CDC Home | CDC Search | Health Topics A-Z

This page last reviewed May 16, 2006

Emerging Infectious Diseases Journal
National Center for Infectious Diseases
Centers for Disease Control and Prevention